CN115942935B - 包括氯胺酮的微球制剂及其制备和使用方法 - Google Patents

包括氯胺酮的微球制剂及其制备和使用方法

Info

Publication number
CN115942935B
CN115942935B CN202180050934.4A CN202180050934A CN115942935B CN 115942935 B CN115942935 B CN 115942935B CN 202180050934 A CN202180050934 A CN 202180050934A CN 115942935 B CN115942935 B CN 115942935B
Authority
CN
China
Prior art keywords
microsphere
polymer
ketamine
microspheres
homogenizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180050934.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN115942935A (zh
Inventor
瑞秋·加拉斯卡
凯尔西·卡特
特雷西·里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oakwood Laboratories LLC
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Publication of CN115942935A publication Critical patent/CN115942935A/zh
Application granted granted Critical
Publication of CN115942935B publication Critical patent/CN115942935B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
CN202180050934.4A 2020-08-18 2021-08-17 包括氯胺酮的微球制剂及其制备和使用方法 Active CN115942935B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063067068P 2020-08-18 2020-08-18
US63/067,068 2020-08-18
US202163149911P 2021-02-16 2021-02-16
US63/149,911 2021-02-16
PCT/US2021/046220 WO2022040130A1 (en) 2020-08-18 2021-08-17 Microsphere formulations comprising ketamine and methods for making and using the same

Publications (2)

Publication Number Publication Date
CN115942935A CN115942935A (zh) 2023-04-07
CN115942935B true CN115942935B (zh) 2025-09-05

Family

ID=80270269

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180050934.4A Active CN115942935B (zh) 2020-08-18 2021-08-17 包括氯胺酮的微球制剂及其制备和使用方法

Country Status (10)

Country Link
US (1) US12233165B2 (cg-RX-API-DMAC7.html)
EP (1) EP4199917B1 (cg-RX-API-DMAC7.html)
JP (1) JP7814375B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230052915A (cg-RX-API-DMAC7.html)
CN (1) CN115942935B (cg-RX-API-DMAC7.html)
AU (1) AU2021329820A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191160A1 (cg-RX-API-DMAC7.html)
IL (1) IL300547A (cg-RX-API-DMAC7.html)
TW (1) TWI906350B (cg-RX-API-DMAC7.html)
WO (1) WO2022040130A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
EP4611729A1 (en) * 2022-10-31 2025-09-10 Oakwood Laboratories, LLC Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO2013119183A1 (en) * 2012-02-06 2013-08-15 Nanyang Technological University Methods of manufacturing core-shell microparticles, and microparticles formed thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720859B2 (ja) * 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6479007B1 (en) 1999-09-16 2002-11-12 University Technology Corporation Apparatus and method for controlling pore size in polymeric membranes and thin films
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
WO2002089767A1 (en) * 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050260272A1 (en) 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
CA2620374C (en) 2005-09-28 2012-12-11 Thomas Meyer Pharmaceutical compositions for the treatment of inner ear disorders
EP1996243B1 (en) * 2006-01-11 2014-04-23 HyperBranch Medical Technology, Inc. Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
US20070292521A1 (en) * 2006-06-20 2007-12-20 Schwitzer Co., Ltd Oral Encapsulated Preparation for Aquatic Animals
US20110027331A1 (en) 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP3368553B1 (en) 2015-10-27 2023-08-02 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
SG11202001206YA (en) 2017-09-14 2020-03-30 Agency Science Tech & Res Emulsions, methods and uses thereof
SG11202005896WA (en) 2017-12-22 2020-07-29 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3968979B1 (en) 2019-05-15 2026-07-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
KR102474965B1 (ko) 2019-07-01 2022-12-07 오크우드 레버러토리즈, 엘엘씨 마이크로스피어 및 에멀션 제조하기 위한 시스템 및 방법
WO2021108801A2 (en) 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists
IL294089B1 (en) 2019-12-20 2026-07-01 Alar Pharmaceuticals Inc Injectable, long-acting formulations of ketamine pamoate salts
US20210361578A1 (en) 2020-04-03 2021-11-25 University Of Iowa Research Foundation Mek1/2 inhibitor-loaded microparticle formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
WO2013119183A1 (en) * 2012-02-06 2013-08-15 Nanyang Technological University Methods of manufacturing core-shell microparticles, and microparticles formed thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioerodable Ketamine-Loaded Microparticles Fabricated Using Dissolvable Hydrogel Template Technology;Minze Zhu等;《Journal of Pharmaceutical Sciences》;20171026;第108卷(第3期);1220-122 *
Novel polymeric bioerodable microparticles for prolonged-release intrathecal delivery of analgesic agents for relief of intractable cancer-related pain;Felicity Y Han等;《Journal of Pharmaceutical Sciences》;20150519;第104卷(第7期);2334-2344 *

Also Published As

Publication number Publication date
IL300547A (en) 2023-04-01
JP2023538901A (ja) 2023-09-12
EP4199917C0 (en) 2026-01-07
EP4199917A4 (en) 2024-10-30
KR20230052915A (ko) 2023-04-20
US12233165B2 (en) 2025-02-25
US20220054420A1 (en) 2022-02-24
EP4199917A1 (en) 2023-06-28
TWI906350B (zh) 2025-12-01
WO2022040130A1 (en) 2022-02-24
CN115942935A (zh) 2023-04-07
CA3191160A1 (en) 2022-02-24
JP7814375B2 (ja) 2026-02-16
AU2021329820A1 (en) 2023-03-09
EP4199917B1 (en) 2026-01-07
TW202227044A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
JP6678571B2 (ja) 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法
JP2016513721A5 (cg-RX-API-DMAC7.html)
JP6249584B2 (ja) 薬物含有徐放性微粒子の製造方法
JP7814375B2 (ja) ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
US20160317453A1 (en) High drug load buprenorphine microspheres and method of producing same
WO2022198167A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same
WO2022183196A1 (en) Microsphere formulations comprising lurasidone and methods for making and using the same
US20240216280A1 (en) Microsphere formulations comprising nalmefene andmethods for making and using the same
US20230225993A1 (en) Microsphere formulations comprising ketamine and methods for making and using the same
ES3061392T3 (en) Microsphere formulations comprising ketamine and methods for making and using the same
WO2023133554A2 (en) Microsphere formulations comprising ketamine and methods for making and using the same
US20240342115A1 (en) Microsphere formulations comprising ketamine and methods formaking and using the same
US20250032451A1 (en) Microsphere formulations comprising asenapine and methods for making and using the same
WO2025117624A1 (en) Microsphere formulations comprising brexpiprazole and methods for making and using the same
JP2026507990A (ja) オクトレオチドを含む混合放出プロファイルポリマーミクロスフェア製剤ならびにその製造方法及び使用方法
KR20230154222A (ko) Btk 억제제를 포함하는 마이크로스피어 제제 및 이의 제조 및 사용 방법
WO2024163997A1 (en) Microsphere formulations comprising naltrexone and methods for making and using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant